CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
Operating Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank58
3Y CAGR+21.2%
5Y CAGR-34.7%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+21.2%/yr
Annual compound
5Y CAGR
-34.7%/yr
Recent acceleration
Percentile
P58
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 12.34% |
| 2024 | -53.89% |
| 2023 | 49.42% |
| 2022 | 6.93% |
| 2021 | -2363.38% |
| 2020 | 103.74% |
| 2019 | -86.01% |
| 2018 | -144.33% |
| 2017 | 8484.50% |
| 2016 | 92.59% |